Measurement and clinical implication of circulating antibodies against carcinoembryonic antigen in patients with colorectal carcinoma

WU Xiao-jun,PAN Zhi-zhong,FANG Yu-jing,CHEN Gong,LU Zh,DING Pei-rong,LI Li-ren,KONG Ling-heng
2009-01-01
Abstract:Objective To evaluate the clinical significance of anti-CEA antibodies in the serum of patients with colorectal carcinoma.Methods In the prospective study,complete data of 69 patients with colorectal carcinoma in 2002 were collected. Control groups included 28 patients with benign intestinal conditions and 37 healthy volunteer blood donors. CEA was tested by electrochemiluminescence immunoassay (ECLIA). The immune globulin was measured by immunonphelometry. Tumor tissue CEA was detected by immunohistochemistry. Circulating antibodies against CEA were measured by an indirect enzyme-linked immunosorbent assay (ELISA). The specificity of the anti-CEA antibodies was performed by inhibition assay.Results CEA was elevated (≥5 ng/mL) in 26 out of 69 patients (37.7%) and was not undetectable among the control groups. Anti-CEA antibodies of the IgG or IgM isotype were detected in 44 out of 69 patients (63.8%),whereas in 3 out of 28 benign intestinal conditions (10.7%) and in 4 out of 37 health blood donors (10.8%). All the differences were statistically significant (P<0.05). Anti-CEA antibody had statistically correlation with CEA levels,lymph nodes metastasis and the staging of Dukes'(P<0.05). Anti-CEA antibody was a statistically significant independent favorable factor in recurrence-free survival.Conclusion Anti-CEA antibodies can be detected in a significant proportion of the colorectal cancer patients as a as a tumor marker complementary to CEA. Their presence is associated with improved recurrence-free survival. These results need to be confirmed in large well-controlled randomized clinical trials (RCT).
What problem does this paper attempt to address?